• Sign In
  • Sign Out
  • My Account
Subscribe
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
  • Special reports
Clarivate
  • Data Snapshots
  • BioWorld
  • BioWorld MedTech
  • Infographics: Dynamic digital data analysis
  • Index insights
  • Special reports
  • Infographics: Dynamic digital data analysis
  • Trump administration impacts
  • Biopharma M&A scorecard
  • BioWorld 2024 review
  • BioWorld MedTech 2024 review
  • BioWorld Science 2024 review
  • Women's health
  • China's GLP-1 landscape
  • PFA re-energizes afib market
  • China CAR T
  • Alzheimer's disease
  • Coronavirus
  • More reports can be found here

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
Home » Newsletters » BioWorld

BioWorld

July 10, 2012

View Archived Issues

Three Biotechs Cut Staff, Pursue Divergent Paths

Canadian biotechs QLT Inc. and Cardiome Pharma Corp. disclosed significant downsizings Monday, but the same strategic move put the companies on opposite business trajectories. Read More

Lux Targets 2013 Refiling for Voclosporin in Uveitis

Nearly two years after a complete response letter (CRL) delayed Lux Biosciences Inc.'s plans for oral voclosporin in noninfectious uveitis, the Jersey City, N.J.-based biotech completed patient enrollment in a new Phase III study aimed at addressing the FDA's request for additional clinical data. Read More

PsiOxus Lands $34M to Create 4 Years of Runway for ColoAd1

LONDON – PsiOxus Therapeutics Ltd. has raised £22 million (US$34 million) in its Series B round to finance the first clinical trial of its systemically acting oncolytic virus ColoAd1, in a 132-patient colorectal cancer study that will get under way in September. Read More

Audeo Files for $60M IPO for Late-Stage Cancer Products

Audeo Oncology Inc. filed for a $60 million initial public offering (IPO) to support clinical trials of its products based on hyaluronic acid chemotransport technology (HyACT) for cancer. The HyACT platform is designed to boost the effectiveness of cancer drugs without increasing toxicity. Read More

FDA Approves REMS for Most Powerful Opioids

In the latest salvo against the growing problem of prescription drug abuse and misuse, the FDA approved a classwide risk evaluation and mitigation strategy (REMS) for extended-release and long-acting opioid drugs. Read More

Stock Movers

Read More

Wilex Banks $17.5M Prometheus Payment for Rencarex Milestone

Opting for cash now rather than product sales later, Wilex AG decided to take a payment of $17.5 million as part of the deal it entered last year on the U.S. rights to its Phase III cancer antibody Rencarex (girentuximab) with Prometheus Laboratories Inc. It also stands to get another $2.5 million as part of a revised milestone payment that is contingent on a regulatory filing for the drug. Read More

Other News To Note

• Cangene Corp., of Winnipeg, Manitoba, granted Camurus AB, of Lund, Sweden, exclusive U.S. commercialization rights for episil in managing pain associated with oral lesions, including oral mucositis, resulting from cancer therapy and other causes. Financial terms were not disclosed. Read More

Clinic Roundup

• OncoSec Medical Inc., of San Diego, received Investigational Review Board (IRB) approval at the University of California San Francisco Helen Diller Family Comprehensive Cancer Center for a Phase II trial evaluating OncoSec's OMS ElectroImmunotherapy to treat cutaneous T-cell lymphoma. Read More

Pharma: Other News To Note

• Eli Lilly and Co., of Indianapolis, and Bristol-Myers Squibb Co., of New York, said Erbitux (cetuximab) in combination with chemotherapy regimen Folfiri (irinotecan, 5-fluorouracil, leucovorin) is the first biologic treatment regimen in nearly a decade to receive FDA approval for newly diagnosed metastatic colorectal cancer. Read More

Pharma: Clinic Roundup

• Bayer HealthCare Pharmaceuticals Inc., a Wayne, N.J.-based subsidiary of Bayer AG, began enrolling patients in an international Phase II/III trial to evaluate BAY94-9027 as a prophylactic and on-demand treatment of hemophilia A. Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for July 2, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for July 2, 2025.
  • Medtronic Vitalflow ECMO

    Medtronic receives CE mark for its Vitalflow ECMO system

    BioWorld MedTech
    Medtronic plc received a CE mark for its Vitalflow extracorporeal membrane oxygenation (ECMO) system, which provides temporary support for the heart and lungs in...
  • Drug vials

    Industry could feel fallout of Pfizer vaccine scrutiny

    BioWorld
    In subpoenaing a former Pfizer Inc. official to appear before the U.S. House Judiciary Committee July 22, Judiciary Chair Jim Jordan, R-Ohio, signaled legislative...
  • Illustration of the β2-adrenergic receptor

    Exercise-mimicking compound offers alternative to GLP-1 therapies

    BioWorld
    An experimental drug for treating diabetes and obesity has been shown to lower blood sugar levels and increase fat burning. It is a β2-adrenergic receptor (β2AR)...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe